HARVARD BIOSCIENCE INC

Major Shareholding Notification • Nov 14, 2024

SC 13G/A 1 p24-3162sc13g.htm HARVARD BIOSCIENCE INC

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.3)*
Harvard Bioscience,
Inc.
(Name of Issuer)
Common Stock, par
value $0.01 per share
(Title of Class of Securities)
416906105
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
ý	Rule 13d-1(b)
¨	Rule 13d-1(c)
¨	Rule 13d-1(d)
(Page
1 of 7 Pages)

---

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Page; Sequence: 1; Options: NewSection; Value: 2

CUSIP No. 416906105 13G/A Page 2 of 7 Pages

Field: /Page

1	NAME OF REPORTING PERSON 272 Capital LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,555,820
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,555,820
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,555,820
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.6%
12	TYPE OF REPORTING PERSON IA, PN

Field: Page; Sequence: 2; Value: 2

CUSIP No. 416906105 13G/A Page 3 of 7 Pages

Field: /Page

1	NAME OF REPORTING PERSON Wes Cummins
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,555,820
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,555,820
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,555,820
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.6%
12	TYPE OF REPORTING PERSON IN

Field: Page; Sequence: 3; Value: 2

CUSIP No. 416906105 13G/A Page 4 of 7 Pages

Field: /Page

Item 1(a).
Harvard Bioscience, Inc. (the “ Issuer ”)

Item 1(b).
84 October Hill Road, Holliston, MA 01746

Item 2(a).
This statement is filed by: (i) 272 Capital LP, a Delaware limited partnership (“ 272 Capital ”), with respect to the shares of Common Stock directly held by 272 Capital Master Fund Ltd. (“ Fund ”) to which 272 Capital acts as investment manager, and other advisory accounts of 272 Capital and (ii) Wes Cummins (“ Mr. Cummins ”, and together with 272 Capital, the “ Reporting Persons ”), who is the President of 272 Capital.
The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

Item 2(b).
The address of the business office of each of the Reporting Persons is 3811 Turtle Creek Blvd, Suite 2125, Dallas, TX 75219.

Item 2(c).
272 Capital is a Delaware limited partnership. Mr. Cummins is a United States citizen.

Item 2(d).
Common Stock, par value $0.01 per share (the “ Common Stock ”)

Item 2(e).
416906105

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(a)	¨	Broker or dealer registered under Section 15 of the Act;
(b)	¨	Bank as defined in Section 3(a)(6) of the Act;
(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act;
(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940;

Field: Page; Sequence: 4; Value: 2

CUSIP No. 416906105 13G/A Page 5 of 7 Pages

Field: /Page

(e)	þ	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)	¨	An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
(g)	þ	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit
Insurance Act;
(i)	¨	A church plan that is excluded from the definition of an investment company
under Section 3(c)(14) of the Investment Company Act;
(j)	¨	A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
specify the type of institution: ________ .

Item 4.
The percentages set forth herein are calculated based upon 43,610,883 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024.
The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

Item 5.
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

Item 6.
See Item 2.

Item 7.
Not applicable.

Item 8.
Not applicable.

Field: Page; Sequence: 5; Value: 2

CUSIP No. 416906105 13G/A Page 6 of 7 Pages

Field: /Page

Item 9.
Not applicable.

Item 10.
Each Reporting Person hereby makes the following certification:
By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Field: Page; Sequence: 6; Value: 2

CUSIP No. 416906105 13G/A Page 7 of 7 Pages

Field: /Page

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: November 14, 2024

272 Capital LP
By:	/s/ Wes Cummins
Name: Wes Cummins
Title: President
Wes Cummins
By:	/s/ Wes Cummins
Name: Wes Cummins